April 5, 2024 News by Patricia Inacio, PhD PoNS device made available to US veterans through new collaboration Helius Medical Technologies is collaborating with Lovell Government Services to make its PoNS deviceĀ ā designed to improve walking ability in people withĀ multiple sclerosis (MS) ā available to U.S. veterans and MS patients in other federal healthcare systems. The PoNS device, officially named the Portable Neuromodulation Stimulator, is…
July 17, 2023 News by Marisa Wexler, MS Use of oral DMTs grew substantially since their launch: US study Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased substantially, while injectable DMTs have become less popular, according to a study based on U.S. commercial health insurance data. āWhile two injectable therapies known as platform injectables, were once the…
April 7, 2021 News by Marta Figueiredo, PhD Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosisĀ (MS) patients switching treatment, according to the latestĀ Spherix Global Insightsā report. The launch of MS generics, bioequivalents, and new brands in the U.S. market over the past year has increased…
October 20, 2020 News by Marta Figueiredo, PhD Majority of MS Patients in US Report Mistreatment by Caregivers in Survey In a nationwide survey of caregiver abuse and neglect among Americans withĀ advanced multiple sclerosisĀ (MS), more than half of respondents reported some form of mistreatment, with psychological and financial abuse being the most common. Having a caregiver with a mental illness was the greatest risk factor for mistreatment, the survey…
June 18, 2020 News by Joana Carvalho, PhD Depression 2 to 3 Times More Likely in MS Patients Than Others, Study Finds A likelihood of depression is two to three times higher inĀ multiple sclerosis (MS) patients in the U.S. and U.K. than in similar groups of people in these countries without the disease, a study reported. This risk was also “most evident in the first five yearsĀ after MS diagnosis” among…
December 12, 2019 News by Patricia Inacio, PhD Pediatric MS Affects More Girls Than Boys in US, Analysis of KID Data Shows Records from theĀ Kid’s Inpatient DatabaseĀ (KID) ā the largest database of pediatric patients admitted to hospitals in the U.S. ā show that more than twice as many girls as boys were diagnosed withĀ multiple sclerosisĀ (MS) in 2016. The data shows that 259 boys and 610 girls younger than age 18…
October 11, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Lower Mortality Rate in US, Sweden for MS Patients Treated With Rituximab, Study Reports Treatment of multiple sclerosis (MS) patients with rituximab leads to lower-than-reported mortality rates, according to a large real-world study in the U.S. and Sweden. The findings also revealed no deaths due to infusion reactions or to systemic inflammation. The study, āMortality rates in large US and…
April 4, 2016 News by Patricia Silva, PhD Young MS Patients in the US More Likely to Be Overweight and Suffer More Relapses Than Peers Elsewhere, Study Finds Scientists at the Pediatric MS Center at NYU Langone, New York, reported that U.S. adolescents withĀ multiple sclerosis (MS) receivingĀ interferon-beta 1a therapyĀ had a higher body mass index (BMI), more relapses, and were managed differently compared to patients of similar age in seven other countries. The study, “Subcutaneous…